Newer antithrombotic drugs

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Discovery

Background:

• Thromboembolic disorders pose a significant global health burden, causing substantial mortality and disability.
• Existing antithrombotic therapies, including antiplatelets and anticoagulants, have limitations such as side effects and drug interactions.
• Despite advancements, there is a continuous need for safer and more efficacious drugs to manage arterial and venous thrombosis.

Purpose of the Study:

• To review the current landscape of antithrombotic drug development.
• To highlight the limitations of existing treatments and the necessity for novel therapeutic agents.
• To discuss the mechanisms and ongoing research in developing advanced antithrombotic medications.

Main Methods:

• Literature review of existing and emerging antithrombotic drugs.
• Analysis of drug classes, including antiplatelets (e.g., Aspirin, Clopidogrel, Prasugrel, Ticagrelor) and anticoagulants (e.g., Warfarin, direct thrombin inhibitors, Factor Xa inhibitors).
• Discussion of drug mechanisms, clinical applications, and research trends in thromboembolic disorder management.

Main Results:

• Aspirin, Clopidogrel, Ticlopidine, and GpIIb/IIIa inhibitors are established treatments.
• Warfarin remains in use but faces challenges due to side effects and interactions.
• Newer agents like Prasugrel, Ticagrelor, Cangrelor, Ximelgatran, Dabigatran, Apixaban, and Idrabiotaparinux represent advancements in antithrombotic therapy.

Conclusions:

• The development of novel antithrombotic drugs is crucial for improving patient outcomes in thromboembolic disorders.
• Ongoing research focuses on enhancing drug safety and efficacy by targeting specific steps in thrombus formation.
• The field continues to evolve, with new direct oral anticoagulants and antiplatelet agents offering improved therapeutic options.